China’s new commercial insurance model could broaden access to Alzheimer’s drugs

Chi­na’s new com­mer­cial in­sur­ance for­mu­la­ry looks to ex­pand pa­tient ac­cess to Alzheimer’s dis­ease med­i­cines from Eli Lil­ly and Ei­sai while po­ten­tial­ly boost­ing rev­enue for the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.